Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GALE $2.29 0.2100 +10.10%
EPZM $23.35 1.6900 +7.80%
SPPI $7.18 0.2800 +4.06%
BDSI $8.66 0.1900 +2.24%
NYMX $5.24 0.0900 +1.75%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PARD $0.21 -0.1099 -34.34%
IMNP $3.96 -0.5300 -11.80%
TGTX $5.16 -0.6600 -11.34%
IMMU $4.15 -0.4200 -9.19%
GERN $2.00 -0.1900 -8.68%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

CEO Roundtable on Cancer Launches the Project Data Sphere Initiative, A New Data Sharing and Analytic Platform for Cancer Patient Benefit

(Yahoo! Finance) Apr 8, 2014 - Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (, with the goal of advancing research to improve the lives of cancer patients and their families around the world.
read article 

N-of-One Selected by Dartmouth-Hitchcock Norris Cotton Cancer Center to Provide Clinical Interpretation for Molecular Diagnostics Program

(Yahoo! Finance) Apr 8, 2014 - N-of-One, Inc. today announced an agreement with Dartmouth-Hitchcock Medical Center in Lebanon, NH to provide clinical interpretation for Dartmouth-Hitchcock’s Next-Generation Sequencing tests as part of Norris Cotton Cancer Center’s comprehensive molecular diagnostics and treatment program.
read article 

Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS® (Brentuximab Vedotin) in Key Countries

(MarketWatch) Apr 8, 2014 - Seattle Genetics, Inc. will receive milestone payments from Takeda Pharmaceutical Company Limited totaling $6 million as a result of achieving the first commercial sale of ADCETRIS (brentuximab vedotin) in three key countries in Takeda’s territories outside of the European Union and Japan, consisting of Australia, South Korea and Mexico.
read article 

Turkish Drug Exporter Ozay Draws U.S. Scrutiny

(Wall Street Journal) Apr 7, 2014 - U.S. officials say they have traced much of the illicit cancer medication that has turned up in U.S. doctors' offices in recent years to Ozay Pharmaceutical, a small Turkish company.
read article (paid subscription required) 

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis®

(MarketWatch) Apr 7, 2014 - Myriad Genetics, Inc. today announced that it has submitted the first module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for the use of BRACAnalysis® testing as a companion diagnostic with olaparib.
read article 

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

(Pharmacyclics) Apr 8, 2014 - Pharmacyclics, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATE(TM) study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICA(TM) (ibrutinib) versus ofatumumab in 391 patients with CLL or SLL, who had received at least one prior therapy.
read corporate press release 

Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial

(Reuters) Apr 8, 2014 - Ambit Biosciences today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
read article 

Not So Fast: Dividing Cells Use a “Speed Limit” to Avoid Genetic Mistakes

(MSKCC/OnCancer blog) Apr 8, 2014 - One of the main functions of the nucleus is to protect the cell’s chromosomes, or DNA molecules, and preserve their genetic information when the cell divides.
read article 

For Teen Girls, Fruits and Veggies Linked to Lower Risk of Breast Condition

(Reuters Health) Apr 7, 2014 - Teenage girls who eat more colorful fruits and vegetables are less likely to develop benign breast disease as young adults, according to a new study.
read article 

Circumcision Could Prevent Prostate Cancer… if It’s Performed After the Age of 35

(University of Montreal News) Apr 7, 2014 - Researchers at the University of Montreal and the INRS-Institut-Armand-Frappier have shown that men circumcised after the age of 35 were 45% less at risk of later developing prostate cancer than uncircumcised men.
read press release 

Look for Cancer, and Find It

(New York Times/Well blog) Apr 7, 2014 - Mammography has become a fighting word in recent years, with some researchers questioning its value and others staunchly defending it.
read article 

For Good and Ill, Immune Response to Cancer Cuts Both Ways

(UC San Diego) Apr 7, 2014 - The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a “double-edged sword,” report researchers.
read press release 

Genomic Analysis Yields Abnormalities Associated with Targeted Treatments in Rare and Poor Prognosis Cancers

(Rutgers CINJ) Apr 7, 2014 - Research from Rutgers Cancer Institute of New Jersey shows genomic profiling identifies genomic alterations in tumors that can be associated with targeted therapies in the treatment of rare and poor prognosis cancers.
read press release 

AACR 2014: Thwarting Drug-resistant Lung Cancer with a Novel Compound

(City of Hope) Apr 4, 2014 - A group of City of Hope researchers have identified and synthesized a novel compound — called COH-SR4 — that is effective against drug-resistant lung cancer.
read article 

AACR 2014: Father’s Age at Birth May Affect Daughter’s Cancer Risk

(City of Hope) Apr 7, 2014 - A team of City of Hope researchers, lead by Yani Lu, Ph.D., explored this relationship and found that a parent’s age at birth, particularly a father’s age, may affect the adult-onset cancer risk for daughters — especially for breast cancer.
read article 

AACR 2014: Hormone Therapy Linked to Lower Non-Hodgkin Lymphoma Risk

(City of Hope) Apr 7, 2014 - City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
read article  

Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation

(Fort Mill Times) Apr 7, 2014 - Data supports TLR antagonism as potential therapeutic approach for genetically defined forms of B-cell lymphoma; IMO-8400 in Phase 1/2 trial for Waldenström’s macroglobulinemia.
read article 

Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting

(Halozyme Therapeutics) Apr 8, 2014 - Halozyme Therapeutics, Inc. today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the AACR annual meeting being held in San Diego.
read corporate press release 

Celldex Therapeutics Establishes Preclinical Proof of Concept for New Antibody Drug Conjugate CDX-014; Data Presented at AACR 2014

(MarketWatch) Apr 7, 2014 - Celldex Therapeutics, Inc. today reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines.
read article 

Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

(NASDAQ) Apr 7, 2014 - Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
read article 

Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014

(Yahoo! Finance) Apr 7, 2014 - CUDC-907 modulates expression of certain cytokines/chemokines, potentially targeting tumor microenvironment in addition to direct effects on cancer cells; sensitivity to CUDC-427 may be predicted by alterations in TNF-alpha and XIAP expression.
read article 

OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting

(MarketWatch) Apr 8, 2014 - OncoMed Pharmaceuticals, Inc. today announced data from an oral presentation and eight poster presentations at the AACR Annual Meeting.
read article 

Calithera Biosciences Presents Pharmacodynamic Data on CB-839 at the 2014 American Association for Cancer Research Annual Meeting

(Yahoo! Finance) Apr 8, 2014 - Calithera Biosciences today announced that data for its lead clinical candidate, CB-839, were featured in two presentations at the 2014 AACR Annual Meeting.
read article 

Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer

( Apr 8, 2014 - Immunomedics Inc. today reported results from preclinical studies on the Company's two investigational SN-38-containing antibody drug conjugates (ADCs), IMMU-130 and IMMU-132, that demonstrated a high therapeutic index for both agents.
read article (free registration required) 

Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study

(Yahoo! Finance) Apr 8, 2014 - NOXXON Pharma announced that data from a Phase IIa pilot study in anemic cancer patients treated with lexaptepid pegol (NOX-H94) will be presented today at the annual meeting of the AACR in San Diego, CA.
read article